Diabetic Retinopathy Market Report Scope & Overview:
The diabetic retinopathy market size was valued at USD 9.39 billion in 2024 and is expected to reach USD 15.48 billion by 2032, growing at a CAGR of 6.47% over the forecast period of 2025-2032.
The global diabetic retinopathy market is expanding due to the growing number of diabetes cases, especially in rapidly urbanizing regions. Urban lifestyles often involve unhealthy diets, reduced physical activity, and chronic stress, factors that contribute to poor blood sugar control and increase the risk of developing diabetic retinopathy. In densely populated cities, lower-income groups face challenges, including limited healthcare access and delayed diagnosis, which raises the chances of disease progression. Countries including India and China are experiencing a sharp rise in diabetes-linked eye conditions due to these shifts. As a result, the demand for effective DR diagnosis and treatment is rising globally.
For instance, in January 2025, A Lancet study found that urban adults in India face a 2.5x higher diabetic retinopathy risk than rural populations due to lifestyle and delayed diagnosis.
The U.S. diabetic retinopathy market was valued at USD 3.02 billion in 2024 and is expected to reach USD 4.92 billion by 2032, growing at a CAGR of 6.32% from 2025 to 2032.
The U.S. is leading the diabetic retinopathy market in the region owing to high support from Medicare and Medicaid, which provide broad access to advanced treatments, telehealth services, and early diagnosis. Medicare pays for anti-VEGF drugs that the FDA has approved for macular degeneration and upfront teleconsultations, and Medicaid covers screenings and care for low-income people. Dual-eligible creates even better affordability and access. Innovative care delivery models and federal programs support the management of chronic diseases.
For instance, in May 2025, CMS reported a 22% rise in Medicare reimbursements and 15% increase in Medicaid DR screenings, boosting the U.S. diabetic retinopathy market share significantly.
Market Dynamics:
Drivers:
-
Technological Advancements, Driving the Diabetic Retinopathy Market Growth
The diabetic retinopathy market is primarily driven by technological advancements. Imaging tools based on AI, including OCT, enhance early and precise diagnosis, whereas genomics tools contribute to personalized treatments. Real-time monitoring is made possible by IoT devices and wearables, thus improving disease treatment. Other text: Telemedicine widens access to treatment in remote areas, while new drug delivery mechanisms ensure better treatment compliance. Together, these advances increase efficiency, access, and results, and drive the market substantially.
For instance, in February 2025, AAO reported that AI-based diabetic retinopathy tools improved diagnosis speed by 35% and early detection rates by 28%, enhancing patient outcomes significantly.
Restraints:
-
High Cost of Anti-VEGF Therapy, Restraining the Diabetic Retinopathy Market
The high cost of anti-VEGF drugs is a major challenge for the diabetic retinopathy market. Expensive, occasional injections reduce access in low-income areas and challenge health budgets, slowing the adoption of treatment. This limits overall market growth despite increasing demand. But it's also driving the use of biosimilars and innovation in depot therapies. These issues restrict the expansion of the diabetic retinopathy market share, particularly in low-cost and under-insured communities.
For instance, in April 2025, GlobalData reported 42% of DR patients in LMICs discontinued anti-VEGF due to cost, while biosimilar usage rose 31%, moderating market growth.
Segmentation Analysis:
By Type
Non-proliferative diabetic retinopathy was the dominant segment in the diabetic retinopathy market analysis, with a market share of 71.96% share in 2024, owing to the higher incidence among early-stage diabetes patients and after diagnostic work-up. NPDR represents the majority of diabetic retinopathy diagnosed cases, with most patients entering this stage before advancing to proliferative diabetic retinopathy. With the early detection and increasing awareness, the screening programs and AI-powered tools all serve to increase the demand for treatment. This dramatically raises the diabetic retinopathy market share for NPDR-targeted diagnostics and therapies.
Proliferative Diabetic Retinopathy is emerging as the fastest growing segment in the global diabetic retinopathy market with a CAGR of 6.91%, driven by accelerated disease progression in untreated or inadequately treatment of diabetes cases. Growing demand for the advanced treatment, including anti-VEGF therapy and vitrectomy, is one of the key growth factors. This factor has a tremendous positive impact on the overall diabetic retinopathy market growth as severe cases demand intensive and high-cost treatments.
By Management
In 2024, the Anti-VEGF segment controlled the global diabetic retinopathy market share, owing to the established benefit in stopping the progression of the disease and improving visual outcomes, particularly in diabetic macular edema and proliferative phases. It receives wide clinical use, is FDA approved, and enjoys favorable reimbursement. This leadership position greatly amplifies the anti-VEGF diabetes retinopathy treatment market share within developed and emerging health systems.
The Laser Surgery is the fastest-growing segment in the diabetic retinopathy industry, owing to its low cost, availability in resource-limited settings, and proven effectiveness in visual preservation. Demand is fueled further by rising use during early-to-mid DR stages, particularly in low- and middle-income countries. This increase makes a major contribution to the overall market for diabetic retinopathy growth, particularly in areas with a poor supply of anti-VEGF treatments.
Regional Analysis:
In 2024, the North American region dominated the diabetic retinopathy industry and accounted for 38.60% of the overall revenue share, owing to its strong health care system, high diabetes rates, and generous Medicare and Medicaid reimbursement policies. Its leadership is also backed by the use of state-of-the-art technology, including AI-guided retinal screening, OCT imaging, and anti-VEGF therapies. Strong awareness, regular screening, and availability of specialized care contribute to high early diagnosis and treatment rates. The existence of key market players and positive competition among them are the other factors that will supplement market growth. Together, these elements help to drive North America’s global diabetic retinopathy market share and make North America the global focus for advances in both diagnosis and treatment of the condition.
Europe is the second-largest player in the diabetic retinopathy industry market, attributable to the vast patient pool and the geriatric population, lifestyle-related health risks, and strong healthcare infrastructure. High participation in screening programmes, community-driven awareness campaigns supported by the government, and availability of sophisticated treatment methods have resulted in early diagnosis and successful treatment, and the chances of developing colorectal cancer excessively. Competent healthcare professionals and robust R&D also add to the innovative mix, ensuring steady diabetic retinopathy market growth in the region.
The Asia Pacific region is projected to grow with the fastest CAGR of 7.03% over the forecast period, owing to a growing diabetic population, urbanization, and altered lifestyle factors, including an imbalanced diet and a lack of exercise. Diabetes is increasing in epidemic proportions in several countries of the region, particularly India and China, and is directly increasing the prevalence of diabetic retinopathy. Advancements in healthcare infrastructure, increasing awareness about eye health, and growing screening programs are promoting early diagnosis and improved access to treatment. Governments are also putting funds into teleophthalmology and mobile screening efforts targeted at the rural masses. Furthermore, the rising accessibility of more affordable treatments and biosimilars is simplifying the care of DRONGL.
The Middle East & Africa are also developing as a potential market in the diabetic retinopathy industry, as diabetes is on the rise in urban areas. But, poor and inadequate access to specialized eye care, lack of awareness, and under developed health delivery system do not assist in early diagnosis and management. Continuous initiatives by both the government and NGOs to increase the number of screening programs and expand healthcare access are aiding the diabetic retinopathy market growth in some of countries of the region.
The diabetic retinopathy market in Latin America is also rising due to the increasing diabetic affected population and high urbanization. Nevertheless, health disparities, limited availability of sophisticated disease management, and poor screening rates are barriers that limit disease management across the population. Public health programs and awareness campaigns instituted by governments in the region are leading to early detection. These factors are increasingly contributing toward the growth of the diabetic retinopathy market in major countries, including Brazil, Mexico, and Argentina.
Key Players:
Diabetic retinopathy companies include Regeneron Pharmaceuticals, Inc., Roche Holding AG / Genentech, Novartis AG, Bayer AG, Alimera Sciences, Inc., Allergan, Carl Zeiss Meditec AG, Topcon Corporation, Optos plc, Eyenuk, Inc., and other players.
Recent Developments:
-
In February 2025, Regeneron launched Eylea HD (8mg) in the U.S. after FDA approval, offering extended dosing intervals for diabetic retinopathy and improving patient adherence and treatment outcomes.
-
In May 2024, Bayer presented real-world data at ARVO 2024 showing Eylea’s effectiveness in Asian DR patients, reinforcing its clinical value and supporting wider adoption in regional treatment protocols.
-
In October 2024, AbbVie (Allergan) initiated development of a next-generation corticosteroid implant for diabetic retinopathy, aiming for extended drug release and reduced injection frequency to improve long-term treatment adherence.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 9.39 billion |
| Market Size by 2032 | USD 15.48 billion |
| CAGR | CAGR of 6.47% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Proliferative Diabetic Retinopathy, Non-proliferative Diabetic Retinopathy) • By Management(Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Regeneron Pharmaceuticals, Inc., Roche Holding AG / Genentech, Novartis AG, Bayer AG, Alimera Sciences, Inc., Allergan, Carl Zeiss Meditec AG, Topcon Corporation, Optos plc, Eyenuk, Inc., and other players |
Table of Content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence & Prevalence (2023)
5.2 Prescription Trends (2023)
5.3 Device Volume and Usage Trends (2020–2032)
5.4 Healthcare Spending – Government & Out-of-Pocket (2023)
5.5 Software/IT Integration – AI & Teleophthalmology (2023)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Diabetic Retinopathy Market Segmentation By Type
7.1 Chapter Overview
7.2 Proliferative Diabetic Retinopathy
7.2.1 Proliferative Diabetic Retinopathy Trend Analysis (2021-2032)
7.2.2 Proliferative Diabetic Retinopathy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Non-proliferative Diabetic Retinopathy
7.3.1Non-proliferative Diabetic Retinopathy Trends Analysis (2021-2032)
7.3.2 Non-proliferative Diabetic Retinopathy Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Diabetic Retinopathy Market Segmentation By Management
8.1 Chapter Overview
8.2 Anti-VEGF
8.2.1 Anti-VEGF Market Trends Analysis (2021-2032)
8.2.2 Anti-VEGF Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Intraocular Steroid Injection
8.3.1 Intraocular Steroid Injection Market Trends Analysis (2021-2032)
8.3.2 Intraocular Steroid Injection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Laser Surgery
8.4.1 Laser Surgery Market Trends Analysis (2021-2032)
8.4.2 Laser Surgery Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Vitrectomy
8.5.1 Vitrectomy Market Trends Analysis (2021-2032)
8.5.2 Vitrectomy Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Diabetic Retinopathy Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.4 North America Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.5.2 USA Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.6.2 Canada Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.7.2 Mexico Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Diabetic Retinopathy Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.4 Europe Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.5.2 Germany Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.6.2 France Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.7.2 UK Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.8.2 Italy Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.9.2 Spain Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.10.2 Poland Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.11.2 Turkey Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Diabetic Retinopathy Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.4 Asia Pacific Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 China Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 India Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 Japan Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.6.2 South Korea Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.7.2 Singapore Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
8.4.8.2 Australia Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Diabetic Retinopathy Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.5.2 UAE Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.7.2 Qatar Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.8.2 South Africa Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Diabetic Retinopathy Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.4 Latin America Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.5.2 Brazil Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.6.2 Argentina Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Diabetic Retinopathy Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Diabetic Retinopathy Market Estimates and Forecasts, By Management (2021-2032) (USD Billion)
10. Company Profiles
10.1 Regeneron Pharmaceuticals, Inc.
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Roche Holding AG / Genentech
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Novartis AG
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Bayer AG
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Alimera Sciences, Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Allergan
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Carl Zeiss Meditec AG
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Topcon Corporation
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Optos plc
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
-
-
-
SWOT Analysis
-
-
10.10 Eyenuk, Inc.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
Key Segments:
By Type
-
- Proliferative Diabetic Retinopathy
- Non-proliferative Diabetic Retinopathy
By Management
-
- Anti-VEGF
- Intraocular Steroid Injection
- Laser Surgery
- Vitrectomy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Poland
- Turkey
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g. Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
